# ⬡ ChemoFilter: Metabolic Stability & Clearance Descriptors

**The Engineering of Pharmacokinetic Half-Life Prediction**  
*Understanding Tier 7 (Celestial Engine) Metabolic Stability Logic*

---

## 1. Executive Overview

A drug candidate with high potency but poor metabolic stability will never achieve therapeutic concentrations in the blood. **Metabolic Stability** refers to the susceptibility of a compound to biotransformation, primarily by Cytochrome P450 (CYP) enzymes in the liver. 

ChemoFilter's **Tier 7 (Celestial Engine)** predicts metabolic liability markers to estimate the half-life ($T_{1/2}$) of the compound.

---

## 2. CYP450 Isoenzyme Inhibition (SMARTS Mapping)

ChemoFilter uses a local fragments-based lookup to identify structural motifs known to inhibit or compete for five major CYP450 isoforms:

*   **CYP3A4:** The "workhorse" enzyme (metabolizes ~50% of drugs).
*   **CYP2D6:** Responsible for many CNS drug metabolisms.
*   **CYP2C9, CYP2C19, CYP1A2:** Secondary metabolic pathways.

**Logic:** If a molecule contains an imidazole or certain heterocyclic nitrogens, the engine throws a **"High Metabolic Competition Risk"** flag.

---

## 3. Intrinsic Clearance ($CL_{int}$) Estimation

While experimental $CL_{int}$ requires liver microsomes, ChemoFilter provides an *in silico* estimate based on:
1.  **Fraction of sp3 Carbons ($Fsp3$):** Higher saturation often correlates with higher stability (less prone to aromatic oxidation).
2.  **Number of Metabolic Soft Spots:** Identification of benzylic carbons and unhindered phenols.
3.  **Polarity (TPSA):** Higher polarity often facilitates phase II (glucuronidation) excretion.

---

## 4. Half-Life ($T_{1/2}$) Categorization

Based on the combination of LogP and Tier 7 stability flags, ChemoFilter classifies leads into three bins:

| Category | Predicted Half-Life | Clinical Potential |
| :--- | :--- | :--- |
| **High Stability** | > 8 Hours | Potential for Once-Daily (QD) dosing. |
| **Moderate Stability** | 2–8 Hours | Potential for Twice-Daily (BID) dosing. |
| **Low Stability** | < 2 Hours | Likely requires Prodrug or slow-release formulation. |

---

## 5. Reducing Metabolic Liability

If ChemoFilter flags a **"High Clearance Risk"**:
*   **Deuteration:** Suggesting the replacement of Hydrogen with Deuterium at "soft spots" (The Kinetic Isotope Effect).
*   **Fluorination:** Adding Fluorine to block oxidative metabolism at specific carbon centers (e.g., para-position of a phenyl ring).
*   **Steric Hindrance:** Adding bulk near a reactive group to prevent enzyme access.

---

## 6. How to Extend This Engine

Tier 11 (Phase 4 Roadmap) aims to integrate **GNNs (Graph Neural Networks)** trained on the `MetaboLights` database to provide quantitative $T_{1/2}$ values for specific organ systems (Hepatic vs. Renal).
